Investigation on the use of fused deposition modeling for the production of IR dosage forms containing Timapiprant.

ABSTRACT: The present work focused on evaluating the feasibility of fused deposition modeling (FDM) in the development of a dosage form containing Timapiprant (TMP), also known as CHF6532, which is a novel active molecule indicated in the potential treatment of eosinophilic asthma upon oral administration. The resulting product could be an alternative, with potential towards personalization, of immediate release (IR) tablets used in the clinical studies. Formulations based on different polymeric carriers were screened, leading to the identification of a polyvinyl alcohol-based one, which turned out acceptable for versatility in terms of active ingredient content, printability and dissolution performance (i.e. capability to meet the dissolution specification set, envisaging >80% of the drug di

SUBMITTER: Uboldi M 

PROVIDER: S-EPMC9823139 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature